Last mentioned: Mar 24, 2026
Regulatory Filings
Planned submission of clinical trial applications for ATG-201 in China and Australia.
Profitability Target
Antengene aims to achieve its first full year of profitability.
AACR 2026
Antengene scheduled to present data on next-generation ADCs and TCEs.
2025 FY Results
Company announces full-year results and confirms shift toward 2026 profitability.
Investor Briefings
Antengene hosts dual-language conference calls to discuss the UCB partnership and pipeline impact.
UCB Partnership
Antengene enters into a global license agreement with UCB for ATG-201 for $60M upfront.
Global License Agreement
Antengene and UCB announce the $1.1B+ licensing deal for ATG-201.
Belgian biopharma leader UCB has announced a massive $2 billion investment to construct a new manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-tech jobs and significantly enhance the company's production capacity for its growing immunology and neurology portfolios.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
This page surfaces every story mentioning UCB across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where UCB was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |